#fasenra

[eosinophil-hate-blog]

[biotech-news-feed]

Summary of opinion: Fasenra, 19/09/2024 Positive #BioTech #science

[diginerve]

Respiratory Medicine: Current Trends in Asthma and COPD Management

Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory conditions that are very common, not just in people of one country but worldwide.

Though both problems are distinct, sometimes COPD is mistaken as asthma because the two have almost the same symptoms.

Below is the information that will help you differentiate both: 

Asthma is a chronic inflammatory disease that affects the airways at both a cellular and molecular level. Asthmatics often suffer from allergies, and their symptoms begin in childhood.

COPD, on the other hand, is characterized by impaired airflow that cannot be reversed. It usually develops later in life.

After gaining some insight into the impact of both diseases on health, you might get concerned about the situation. But the good news is that with the increasing number of asthma and COPD patients, awareness and research for better treatment for these conditions have also increased. To ease the lives of people suffering from these issues, our scientists work day and night to create Oral and intravenous corticosteroids. Additionally, students pursuing an MD in medicine put in their 100% effort so that in the future, they can do more advanced-level research and invent new drugs. 

The following are the current Asthma and COPD Management trends that you should be aware of!

Current Trends in Asthma & COPD Management 

Asthma & COPD management aims to control symptoms, prevent exacerbations, and minimize the risk of persistent airflow limitation and asthma-related death.

The following are the current trends in management that you should be aware of if you are interested in studying Respiratory Medicine:

Inhalers and Nebulizers: Inhalable medications such as Fasenra, Dupixent, Ventolin, salbutamol, and terbutaline are the first-line treatments for respiratory diseases. With the advancement of medical science, the market has seen a surge in the development of more efficient and user-friendly inhaler devices, which ensure better compliance and improved drug delivery.

Despite the initial treatment, if you still struggle with the issue, consult with your doctor to pursue a second line of action.

For Asthma, second-line drugs include heliox, magnesium sulfate, ketamine, and inhalational anesthetics.

For COPD,second-line options include tiotropium, salmeterol (Serevent), formoterol (Foradil), ipratropium, albuterol/ipratropium (Combivent), and levalbuterol (Xopenex).

Biologics Medicine: The emerging trends in therapies for lung diseases have pointed toward the use of monoclonal humanized antibodies, which are referred to as biologics.

These therapies target the specific immune system components responsible for asthma and COPD, increasing the chances of better outcomes.

Digital Health Solutions: The digital revolution is not only uplifting our lifestyle but also playing a critical role in improving our health. Now, with the invention of wearable devices that can track respiratory health, patients can help themselves escape serious respiratory conditions where they have to rush to the hospital.

Personalized medicine: Another prominent trend is treatment tailored to the patient's unique genetic and molecular profile. Because every person might have different causes of problems, symptoms, and responses toward particular drugs, this approach should become more common in the coming years. 

Apart from the treatment listed above, for people suffering from asthma and COPD, it is possible to manage their condition before the problem gets out of hand.

The following are the steps they can take:

Identify and avoid triggers like allergens, irritants like smoke and pollution, and respiratory infections.

Get regular vaccinations for influenza and pneumonia.

Quit Smoking

Control weight

Summary: We hope you found the above information helpful. Though the information in the article was basic, if you want in depth knowledge of the Clinical manifestation for COPD and the management of Asthma attack, enroll in our medicine md online course now!

Opt for a Medicine MD course!

This course is designed to address the gaps in clinical skills and help students grasp the subject fully.

The course covers various medical specialties, including Neurology, Cardiology, Gastrointestinal Surgery, Hepatology, Pulmonary and Chest Medicine, and rheumatology. 

So, don’t wait to take a step closer to your dress, enroll in the course now! 

[bidhuan]

Mengenal Injeksi Otomatis Dosis Tunggal Benralizumab Untuk Asma Berat Pada Anak

Mengenal Injeksi Otomatis Dosis Tunggal Benralizumab Untuk Asma Berat Pada Anak

Farmasetika.com – Fasenra (Benralizumab) adalah obat yang telah disetujui oleh FDA (Food and Drug Administration) pada Mei 2019 sebagai obat yang dapat digunakan dalam terapi jangka panjang penyakit asma berat dengan kelainan sel eosinofil yang diderita oleh pasien berumur 12 tahun ke atas.

Asma berat

Pada pasien asma berat, sel eosinofil sendiri merupakan salah satu jenis sel darah putih yang…

[lucadezzani]

Top News from ERS International Congress 2018

Top News from ERS International Congress 2018

All The Most Important News and Updates form the European Respiratory Society International Congress – ERS 2018 People with asthma at higher risk of becoming obese

September 15, 2018

Obesity is known to be a risk factor for developing asthma but a new study shows that the reverse is also true: people with asthma are more likely to go on to become obese. The new research, presented at the European…

[newsintoday-net-blog]

AstraZeneca’s drug Fasenra flops in COPD trial LONDON (Reuters) - AstraZeneca’s said its first respiratory biologic medicine Fasenra failed to meet its target in a clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

[christopherporreca01]

BRIEF-AstraZeneca pricing new severe asthma drug Fasenra below rivals Nov 15 (Reuters) - AstraZeneca: * Says pricing Fasenra below the treatment cost of all other biologics in severe asthma…

[biotech-news-feed]

AstraZenecaâs Fasenra (benralizumab) has recently been approved by the FDA for treating severe asthma in children aged 6 to 11 with the eosinophilic phenotype. #BioTech #science

[bidhuan]

Autoinjektor Benralizumab, Obat Biologis Baru Terapi Mandiri Asma

Autoinjektor Benralizumab, Obat Biologis Baru Terapi Mandiri Asma

Farmasetika.com – Perusahaan obat Inggris AstraZeneca mengatakan pada hari Jumat (4/10/2019) bahwa Administrasi Makanan dan Obat-obatan (FDA) AS telah menyetujui pemberian sendiri pengobatan asma Fasenra (Benralizumab) yang menggunakan pena injektor otomatis sekali pakai.

Persetujuan ini didukung oleh data dari uji coba GRECO Tahap III dan uji coba AMES Tahap I. Keamanan dan tolerabilitas Fasenra…

[lucadezzani]

Top Pharma News | November - December 2017

Top Pharma News | November – December 2017

Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)

November 2, 2017

Boehringer Ingelheim and Dicerna Pharmaceuticals, a leading developer of investigational RNA interference (RNAi) therapeutics, have announced a research collaboration and license agreement to discover and develop novel…

[peoplevssidefx]

“Could you be living a bigger life?” With those side effects? Probably not.

Fasenra - Asthma attack prevention. 

May Cause: Anaphylaxis, breathing problems, dizziness, sore throat, rash, hives, fever, WORSE asthma attacks. 

[pharmaphorumuk]

AZ trumpets tezepelumab data as filing for severe asthma looms

AstraZeneca says full data from the NAVIGATOR trial of tezepelumab in severe asthma keep it on course to file for approval in the first half of this year, with a broader indication than rival biologic drugs. 

Top-line data were reported last year, but a presentation at the American Academy of Asthma Allergy & Immunology (AAAAI) virtual congress today is the first opportunity for doctors to see the dataset in full.

The headline news is that adding tezepelumab to standard therapy for severe asthma cut the annual asthma exacerbation rate (AAER) by 56% over 52 weeks, which an AZ spokesman said was consistent with the benefit seen in the mid-phase PATHWAY trial.

Crucially, NAVIGATOR shows that tezepelumab – a TSLP inhibitor partnered with Amgen – seemed to have a benefit regardless of patients’ levels of eosinophils, a type of white blood cell.

There are already a clutch of biologic drugs approved to treat severe eosinophilic asthma, including Sanofi/Regeneron’s IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ’s own IL-5 inhibitor Fasenra (benralizumab), which competes with GlaxoSmithKline’s Nucala (mepolizumab) and Teva’s Cinqaero (reslizumab).

If approved, tezepelumab could be the first biologic for both eosinophilic and non-eosinophilic asthma, expanding the patient population for which it could be used.

Up to 60% of severe, uncontrolled patients have baselines eosinophil counts <300 cells/µL and current biologics can have reduced efficacy for those patients. And patients with baselines eosinophil counts <150 cells/µL currently lack biologic treatment options completely, the spokesman told pharmaphorum.

In NAVIGATOR, tezepelumab achieved a 41% reduction in AAER in patients with eosinophil levels below 300 cells/µL, with a clinically meaningful fall in 70% of all patients in that group. There was also a clinically meaningful reduction in 39% of the <150 cells/µL group.

“While we can’t make direct comparisons to other biologics because head-to-head trials have not been conducted, the overall efficacy demonstrates tezepelumab’s strong clinical profile for a broad population of severe asthma patients, regardless of their type of inflammation,” he said.

No other biologic has consistently demonstrated a statistically significant reduction in AAER for severe asthma patients with baseline eosinophil counts <300 cells/µL across phase 2 and 3 trials, according to AZ.

The company is adamant that NAVIGATOR and PATHWAY together are sufficient to support approval of tezepelumab, which has been forecast by EvaluatePharma to have sales potential of $1 billion-plus by 2026.

There was a setback for the programme last year however when the phase 3 SOURCE trial missed its main endpoint, with tezepelumab failing to improve on placebo on the measure of reducing the need for oral corticosteroids without loss of asthma symptoms control.

AZ has said it thinks the trial’s design could have resulted in the miss, and points to secondary endpoint data support the findings of its other trials.

“About half of asthma patients have multiple drivers of inflammation and can face debilitating symptoms despite receiving standard of care inhaled medicines and currently approved biologics,” said the spokesman.

“The NAVIGATOR results give tezepelumab a highly competitive and differentiated clinical profile and confirm our plans to bring tezepelumab to a broad population of severe asthma patients – across phenotypes and irrespective of biomarkers,” he added.

AZ meanwhile is looking beyond asthma to try to build the market for the drug.

That includes an ongoing phase 2a trial – called COURSE – which is looking at the efficacy and safety of tezepelumab in chronic obstructive pulmonary disease (COPD)  patients who continue to experience exacerbations despite current “triple therapy”. Results from that are due in 2023.

The post AZ trumpets tezepelumab data as filing for severe asthma looms appeared first on .

from https://pharmaphorum.com/news/az-trumpets-tezepelumab-data-as-filing-for-severe-asthma-looms/

[biotech-news-feed]

Opinion/decision on a Paediatric investigation plan (PIP): Fasenra, Benralizumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Haematology-Hemostaseology, PIP nu #BioTech #science

[shweta2707]

Respiratory Tract Infection Treatment Market Global Overview 2020 | Forecast till 2026

Summary:

Respiratory diseases such as bronchitis, asthma, allergic rhinitis, pneumonia, and sinusitis can significantly curtail the physical activities of the individual. 

The global Respiratory Tract Infection Treatment Market was valued at US$ 35.64 Bn in 2017, and is expected to witness a CAGR of 6.5% over the forecast period (2018 – 2026).

Figure 1. Global Respiratory Tract Infection Treatment Market Share Analysis (%), By Product Type              

                           Market Drivers:

Increasing prevalence of chronic respiratory diseases such as asthma, chronic pulmonary lung disease, pulmonary hypertension, and occupational lung disease are the major factors augmenting growth of the Respiratory Tract Infection Treatment Market.

For instance, according to the Biomed Central Respiratory Research 2016, asthma and chronic obstructive pulmonary disease (COPD) are common chronic obstructive lung disorders characterized by variable airflow limitation and airway hyper responsiveness, affecting over 25 million people in the U.S.

Various organizations, institutions, and agencies are working towards improving the diagnosis and medical care needed to reduce the global burden of respiratory diseases. For instance, the Global Alliance against Chronic Respiratory Diseases (GARD) was formed with the support from the World Health Organization (WHO) to control chronic respiratory diseases. The main objective of GARD is to develop simple and affordable strategies for chronic respiratory diseases (CRD) and to encourage economies to implement health promotion and CRD prevention policies.

Presence of various drugs in pipeline, which is expected to be launched over the forecast period will also boost the market growth of respiratory tract infection treatment. Some of the drugs in the pipeline include Relenza (GSK), MK7264 (Merck & Co.), Presatovir (Gilead), AZD7594, and PT010 (AstraZeneca).

Market Restraint

Presence of various generic manufacturers and low cost of various drugs including antibiotics in the market may hinder the respiratory tract infection treatment market to some extent during the forecast period.

Request for the Sample copy @ https://www.coherentmarketinsights.com/market-insight/respiratory-tract-infection-treatment-market-2030

Segment Information:

North America is expected to hold a dominant position in the global respiratory tract infection treatment market over the forecast period, owing to increasing number of hospitalizations and emergency visits associated with acute or life threatening medical problems.

According to the study by Society of Critical Care Medicine 2016, over 5.7 million patients are admitted annually in intensive care units (ICUs) in the U.S. for support of airway, breathing or circulation, and comprehensive management of injury.

Also, according to the Centers for Disease Control and Prevention (CDC), 2017, around 1.7 million emergency department visits with chronic and unspecified bronchitis were registered in the U.S. hospital facilities.

Furthermore, several pharmaceutical and biotechnological companies are focusing on expanding their business in Asia Pacific region, to maximize their R&D activities, as this region provides better access to patients for clinical trials, with low cost operational efficiencies.

Increasing government investments in research and development, patient awareness, improved health care infrastructure and facilities, high disposable income, and prevalence of unhealthy lifestyle are also expected to foster growth of the respiratory tract infection treatment market in the Asia Pacific region.

Request for the PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2030

Figure 2: Global Respiratory Tract Infection Treatment Market Share (%), By Region

Key Development

Increasing approval of new drugs by the Food and Drug Administration (FDA) is also expected to propel the overall market growth over the forecast period. For instance, in November 2017, the U.S. FDA approved Fasenra (Benralizumab) manufactured by AstraZeneca, a respiratory biologic for patients aged 12 years and older who are suffering from asthma, and with an eosinophilic phenotype.

Key players operating in the global Respiratory Tract Infection Treatment Market include 

Abbott Laboratories, AstraZeneca, Plc, Abbvie Inc., Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, F. Hoffman La Roche Ltd, Sanofi, and Teva Pharmaceutical Industries Ltd.

About Us

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

  Contact Us:

Mr. Shah

Coherent Market Insights Pvt.Ltd.

Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Phone: +1–206–701–6702

Email: sales@coherentmarketinsights.com     

[fromsciencetopharma]

AZ Fasenra shows benefit in chronic rhinosinusitis with nasal polyps #AstraZeneca #NasalPolyps “AstraZeneca’s Fasenra (benralizumab) significantly reduced the size of nasal polyps and cut nasal blockage in patients with chronic rhinosinusitis, raising hopes for a new treatment option for this condition. In the Phase III OSTRO trial, Fasenra showed a statistically significant improvement in the endoscopic total nasal polyp score (NPS) and the nasal blockage score (NBS) compared to placebo, in patients with severe bilateral nasal polyposis who were still symptomatic despite continued treatment with standard of care, the firm said. Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease linked with elevated levels of eosinophils in the upper respiratory tract and characterised by benign growths called nasal polyps, which can cause blockage and discharge, reduction or loss in the sense of smell, sleep disturbances and other adverse effects on quality of life.” #womeninpharmacy #womeninmedicine #msl #medicalaffairs #pharmacist #pharma #medicalscienceliaison #pharmacistmom #pharmacistmoms #pharmd #pharmacy #pharmacystudent #pharmacystudents https://www.instagram.com/p/CFG0qFZjIbf/?igshid=3w08ywliv5hw